QIAGEN and Pathway Diagnostics Sign Agreement to Address Biomarker Development Needs in Pharma

09-Jan-2007

QIAGEN N.V. and Pathway Diagnostics Corporation announced a co-marketing partnership. The new partnership shall allow customers in the biotechnology and pharmaceutical industries to leverage QIAGEN's sample and assay technology platforms in combination with Pathway Diagnostics' clinical development and testing service capabilities. Under the partnership, QIAGEN's global pharmaceutical sales channel and resource network shall develop project opportunities which can be addressed together with the service capabilities of Pathway Diagnostics.

Other news from the department business & finance

Most read news

More news from our other portals

Under the magnifying glass: The world of microscopy